Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) show up everywhere on USMLE because they connect metabolic syndrome ↔ liver injury ↔ cirrhosis/HCC risk. Here’s a quick, shareable way to lock in the essentials—especially the “what is it, who gets it, what does it look like, and why do we care?”
The 10-Second Mnemonic: “NASH is NASTY”
Think of NASH as the “inflamed, injuring” version of fatty liver.
NASH = NASTY
- N = NASH happens in Non-drinkers (or minimal alcohol; history matters)
- A = AST/ALT elevated (often mild–moderate; ALT can be > AST early)
- S = Steatohepatitis = Steatosis + inflammation
- T = Tender hepatomegaly / Two-hit concept (insulin resistance → fat → oxidative injury)
- Y = Yields fibrosis → cirrhosis → HCC risk
One-liner: NAFLD is fat in the liver; NASH is fat + inflammation that can scar.
Visual Device: The “Spectrum Slide” (NAFLD → NASH → Cirrhosis)
Picture a liver sliding down a metabolic hill:
| Stage | What’s in the liver? | Key idea | Why it matters |
|---|---|---|---|
| NAFLD (simple steatosis) | Fat (macrovesicular steatosis) | Often asymptomatic | Can be reversible with weight loss |
| NASH (steatohepatitis) | Fat + inflammation + hepatocyte injury (ballooning) | “Active” injury | Can progress to fibrosis/cirrhosis |
| Fibrosis/Cirrhosis | Scar tissue | Architectural distortion | Portal HTN, liver failure |
| HCC | Malignancy risk rises (esp with cirrhosis) | Screening considerations | Testable complication |
Memory hook:
“Fat is quiet. Fat + fire scars.” (NAFLD quiet; NASH = fire/inflammation → fibrosis)
Who Gets It? (Classic USMLE Risk Cluster)
Think: “NAFLD rides with metabolic syndrome.”
- Obesity
- Type 2 diabetes
- Hypertriglyceridemia/dyslipidemia
- Insulin resistance
- Often HTN as part of the syndrome
USMLE clue: patient with BMI↑, A1c↑, triglycerides↑ and mild transaminitis.
What Do Labs and Imaging Look Like?
High-yield patterns
- Mild–moderate AST/ALT elevation
- Classically ALT > AST in many NAFLD/NASH cases (contrast: alcoholic liver disease often AST:ALT ≥ 2)
- Ultrasound: “bright” liver = hepatic steatosis
- Definitive distinction NAFLD vs NASH: biopsy
- NASH shows ballooning degeneration, inflammation, and may show Mallory-Denk bodies (not exclusive to alcohol)
Board trap: Imaging can tell you “fatty liver,” but it can’t reliably tell NAFLD vs NASH—biopsy is the classic differentiator.
Pathophysiology (Just Enough for Step)
The core idea
- Insulin resistance → increased fatty acid delivery/synthesis in liver → steatosis
- Oxidative stress, mitochondrial dysfunction, cytokines → inflammation + hepatocyte injury
- Injury → fibrosis (and potentially cirrhosis)
If you like formulas: insulin resistance raises hepatic triglyceride accumulation—then inflammation makes it clinically dangerous.
Complications You Must Recognize
- Progression to cirrhosis
- Portal hypertension consequences (ascites, varices, splenomegaly)
- Hepatocellular carcinoma (HCC) risk increases, especially once cirrhosis develops
- Increased cardiovascular risk (common real-world cause of mortality in NAFLD patients)
Management (USMLE Practical Takeaways)
First-line = lifestyle
- Weight loss (can improve steatosis and inflammation)
- Diet + exercise
- Optimize diabetes and lipids
Medication notes (testable nuance)
- No single “magic pill” for everyone; focus is metabolic control.
- In select patients, insulin-sensitizing strategies may be considered, but Step questions usually want:
“Lifestyle modification + treat metabolic syndrome.”
Quick Differentials: Don’t Get Tricked
| Condition | Key clue | Classic AST/ALT pattern |
|---|---|---|
| NAFLD/NASH | Metabolic syndrome, minimal alcohol | Often ALT ≥ AST (variable) |
| Alcoholic liver disease | Heavy alcohol use; macrocytosis | AST:ALT ≥ 2, values usually < 300 |
| Viral hepatitis | Risk factors; very high transaminases possible | AST/ALT can be very high |
| Hemochromatosis | Bronze diabetes, arthropathy | Variable; iron studies abnormal |
Shareable Summary Card (Copy/Paste)
- NAFLD = fat
- NASH = fat + inflammation → fibrosis → cirrhosis/HCC
- Risk factors: obesity, T2DM, hypertriglyceridemia (metabolic syndrome)
- Dx: US shows fatty liver; biopsy distinguishes NASH
- Tx: weight loss + manage metabolic syndrome